Sonoma Pharmaceuticals terminated its Exclusive Supply and Distribution Agreement with EMC Pharma due to EMC's failure to meet minimum purchase requirements, effective November 21, 2024, allowing Sonoma to resume selling its products in the U.S. without penalties.